Skip to main content
Sequana Medical N.V. logo

Sequana Medical N.V. — Investor Relations & Filings

Ticker · SEQUA ISIN · BE0974340722 LEI · 8755009AN12Y4PEOII07 BR Manufacturing
Open in API
Filings indexed 501 across all filing types
Latest filing 2026-04-28 Regulatory Filings
Country BE Belgium
Listing BR SEQUA

About Sequana Medical N.V.

https://www.sequanamedical.com/

Sequana Medical N.V. is a commercial-stage medical device company focused on developing treatments for drug-resistant fluid overload, a frequent complication in patients with liver disease, heart failure, and cancer. The company's primary product is the alfapump®, a fully implanted, wirelessly charged system that automatically and continuously removes ascites (fluid accumulation in the abdomen) into the bladder for natural elimination. It is the first U.S. FDA-approved active implantable medical device for treating recurrent or refractory ascites due to liver cirrhosis, designed to reduce or eliminate the need for therapeutic paracentesis. Sequana Medical is also advancing its DSR® (Direct Sodium Removal) therapy platform, a novel approach for managing fluid overload in heart failure patients.

Recent filings

Filing Released Lang Actions
Sequana Medical -- Announcement Press Release (NL) (28 April 2026).pdf
Regulatory Filings Classification · 90% confidence The document is a regulated press release (“gereglementeerde informatie”) announcing the convening of the annual general shareholders’ meeting, deferral of agenda items (approval of 2025 accounts), a strategic and financial evaluation, and a request to suspend trading. It does not contain the full annual report or AGM presentation materials, nor is it a financial report, proxy statement, or earnings release. It is a general regulatory announcement and thus best fits the fallback category Regulatory Filings (RNS).
2026-04-28 Dutch
Sequana Medical -- Announcement Press Release (ENG) (28 April 2026).pdf
Regulatory Filings Classification · 75% confidence The document is a press release of inside/regulatory information announcing a financial and strategic review, the convening of the Annual General Meeting (to be held 28 May 2026), and a request for suspension of trading due to unavailable financial statements. It is not the Annual Report itself, nor an earnings release, dividend notice, proxy statement or other specific report—it is a general regulatory announcement. Therefore it falls under the fallback category “Regulatory Filings” (RNS).
2026-04-28 English
Sequana Medical -- Announcement Press Release (NL) (28 April 2026).pdf
Regulatory Filings Classification · 72% confidence The document is a regulated press release (‘PERSBERICHT – GEREGLEMENTEERDE INFORMATIE’) announcing a strategic and financial evaluation, the date and postponement of certain agenda items at the upcoming AGM, and a request to suspend trading. It is not the full annual report, audit report, proxy statement, or dividend notice but rather a general regulatory announcement of corporate events. This falls under the general Regulatory Filings category.
2026-04-28 Dutch
Sequana Medical -- 10th GEM -- Closing PR (ENG) (27 April 2026).pdf
Share Issue/Capital Change Classification · 92% confidence The document is a press release announcing a capital increase through subscription of new shares, detailing the new share capital amount and total number of issued shares, and describing outstanding subscription rights and warrants. This clearly corresponds to an announcement of a share issue/capital change, matching the category Share Issue/Capital Change (Code: SHA).
2026-04-27 English
Sequana Medical -- 10th GEM -- Closing PR (NL) (27 April 2026).pdf
Share Issue/Capital Change Classification · 90% confidence The document is a regulated press release announcing a capital increase and detailing the issuance of 598,149 new shares, adjustments to the registered capital and outstanding share count, and attendant share subscription facilities and outstanding warrants/options. This clearly pertains to a share issue and change in capital structure rather than an earnings release, AGM materials, or other categories. Therefore it falls under Share Issue/Capital Change (SHA).
2026-04-27 Dutch
Sequana Medical -- Closing PR (ENG) (26 March 2026).pdf
Capital/Financing Update Classification · 100% confidence The document is a press release dated 26 March 2026 from Sequana Medical announcing a capital increase through the issuance of new shares to GEM Global Yield LLC under a share subscription facility agreement. It details the new share capital amount, the number of shares issued, the subscription facility terms, and outstanding subscription rights and warrants. The content focuses on financing activities, share issuance, and capital structure changes. There are no financial statements or comprehensive financial performance data presented, nor is this a regulatory certification or a report publication announcement. The document fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes.
2026-03-26 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.